These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 24977453)

  • 1. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
    Kasper B; Hohenberger P
    Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
    Verweij J; Sleijfer S
    Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Pazopanib on the Cardiovascular System.
    Justice CN; Derbala MH; Baich TM; Kempton AN; Guo AS; Ho TH; Smith SA
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):387-398. PubMed ID: 29706106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
    Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
    Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
    Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
    McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
    Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
    Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
    Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Atrial flutter probably related to pazopanib: A case report].
    Puebla Villaescusa A; Díaz Gómez E; Salcedo Mingoarranz ÁL; Ramírez Cruz S; Hidalgo Correas FJ; García Díaz B
    Farm Hosp; 2018 Jan; 42(1):33-34. PubMed ID: 29306315
    [No Abstract]   [Full Text] [Related]  

  • 17. Pazopanib for the treatment of renal cell carcinoma.
    Welsh SJ; Fife K
    Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
    Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
    J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.
    Méndez-Vidal MJ; Molina Á; Anido U; Chirivella I; Etxaniz O; Fernández-Parra E; Guix M; Hernández C; Lambea J; Montesa Á; Pinto Á; Ros S; Gallardo E
    BMC Pharmacol Toxicol; 2018 Nov; 19(1):77. PubMed ID: 30477570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
    Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
    Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.